Oncotelic Therapeutics Delays Annual 10-K Filing

Oncotelic Therapeutics ( (OTLC) ) has released a notification of late filing.

Oncotelic Therapeutics, Inc. has filed a Form 12b-25, notifying investors of a delay in submitting its Form 10-K (Yearly Report) for the year ended December 31, 2025. The company, formerly known as Mateon Therapeutics, Inc., is based in Agoura Hills, California, and the late filing concerns its annual report to the U.S. Securities and Exchange Commission.

The company explains that it is still compiling the necessary financial information required to complete the Form 10-K (Yearly Report). Management states that meeting the original deadline would have required unreasonable effort or expense, indicating internal timing and resource constraints rather than an external shock such as an auditor change or regulatory investigation.

Oncotelic Therapeutics expects to submit the delayed Form 10-K (Yearly Report) within the standard SEC extension window. The company has indicated that it plans to file the annual report no later than the fifteenth calendar day following the prescribed due date, which is the maximum extension permitted under the relevant SEC rule for yearly reports.

The company also confirms that all other periodic filings required over the past 12 months have been made on time. Importantly for investors, Oncotelic Therapeutics does not anticipate any significant change in results of operations compared with the prior fiscal year to be reflected in the earnings statements within the upcoming Form 10-K (Yearly Report).

That statement suggests that, while the filing is late, management does not foresee major surprises in the financials versus last year, though investors should remember that this expectation is inherently forward-looking. Actual results, once the Form 10-K (Yearly Report) is filed, may still differ depending on final accounting judgments and audit procedures.

The notification emphasizes the company’s intent to remain in compliance with SEC reporting requirements despite the delay. The Form 12b-25 is signed on behalf of Oncotelic Therapeutics, Inc. by Chief Financial Officer Amit Shah on March 31, 2026, underscoring executive-level responsibility for both the late-filing notice and the forthcoming annual report.

The most recent analyst rating on (OTLC) stock is a Hold with a $0.07 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.

Spark’s Take on OTLC Stock

According to Spark, TipRanks’ AI Analyst, OTLC is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue characteristics, ongoing losses, and continued cash burn) combined with elevated balance-sheet leverage. Technicals also reflect recent weakness (negative MACD; price below key short/intermediate moving averages). Corporate actions around financing and debt milestones provide some support, but they are offset by ongoing dependence on capital markets and dilution risk; valuation signals are limited due to negative earnings.

To see Spark’s full report on OTLC stock, click here.

More about Oncotelic Therapeutics

Average Trading Volume: 300,002

Technical Sentiment Signal: Sell

Current Market Cap: $17.41M

See more data about OTLC stock on TipRanks’ Stock Analysis page.